Skip to content

    Asthma Health Center

    Font Size
    A
    A
    A

    FDA Panel: 3 Asthma Drugs Can Stay

    At Issue: Concern That Drugs May Increase Risk of Asthma Attacks
    By
    WebMD Health News

    July 13, 2005 -- An FDA advisory panel recommended Wednesday that three popular asthma drugs -- Serevent, Advair, and Foradil -- continue to be sold in U.S. pharmacies.

    The FDA often follows the advice of its advisory panels, but it's not required to do so.

    All three drugs are long-acting medications. Serevent and Advair contain an active ingredient called salmeterol.

    Foradil has a different active ingredient but is in the same class of drugs. Panelists stopped short of recommending a "black box" warning for Foradil, which is the most serious type of warning placed on prescription medications. That type of warning now appears on the labels of Serevent and Advair.

    But the panel recommended that Foradil's package insert mention possible safety concerns because Foradil is in the same class of drugs.

    Background

    In August 2003 the FDA added a black box warning to Serevent and Advair.

    At the time, the FDA stated that the warning label for Serevent and Advair was based on a "small but significant increased risk of life-threatening asthma attacks or asthma-related deaths seen in patients taking salmeterol in a recently completed U.S. study."

    The 28-week study was halted in January 2003 by Serevent's maker, GlaxoSmithKline.

    FDA safety reviewer David Graham, MD, voiced concern about Serevent -- as well as other drugs unrelated to asthma -- during congressional drug safety hearings last November.

    The FDA asked for the panel's advice on the topic.

    Regulators were concerned that the drug's warnings were not strong or specific enough because of data suggesting that the drug's risks may be higher for blacks.

    Today, experts expressed worry about the results in blacks but said they don't have enough evidence to make a more specific warning about the drug. Researchers don't know whether apparent safety differences are due to genetic factors, disparities in access to medical care, or both.

    Several experts also said they were reluctant to add a race-based warning that could drive blacks away from the drug.

    When Is Your Asthma Worse?

    When Is Your Asthma Worse?

    Take the WebMD Asthma assessment to get Personalized Action Plan

    Start Now

    Today on WebMD

    Lung and bronchial tube graphic
    5 common triggers.
    group jogging in park
    Should you avoid fitness activities?
     
    asthma inhaler
    Learn about your options.
    man feeling faint
    What’s the difference?
     
    Madison Wisconsin Capitol
    Slideshow
    woman wearing cpap mask
    Article
     
    red wine pouring into glass
    Slideshow
    Woman holding inhaler
    Quiz
     
    Man outdoors coughing
    Article
    Lung and bronchial tube graphic
    Article
     
    10 Worst Asthma Cities
    Slideshow
    runner
    Article